CollPlant Biotechnologies (CLGN) Cash & Equivalents (2018 - 2025)

CollPlant Biotechnologies' Cash & Equivalents history spans 8 years, with the latest figure at $5.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 53.05% year-over-year to $5.6 million; the TTM value through Dec 2025 reached $5.6 million, down 53.05%, while the annual FY2025 figure was $5.6 million, 53.05% down from the prior year.
  • Cash & Equivalents reached $5.6 million in Q4 2025 per CLGN's latest filing, down from $11.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $29.7 million in Q4 2022 to a low of $5.6 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $17.4 million, with a median of $13.1 million recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: soared 272.89% in 2021, then tumbled 55.35% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $13.1 million in 2021, then skyrocketed by 125.53% to $29.7 million in 2022, then decreased by 10.05% to $26.7 million in 2023, then crashed by 55.35% to $11.9 million in 2024, then tumbled by 53.05% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for CLGN's Cash & Equivalents are $5.6 million (Q4 2025), $11.9 million (Q4 2024), and $26.7 million (Q4 2023).